Globus Medical, Inc. (GMED): Price and Financial Metrics


Globus Medical, Inc. (GMED)

Today's Latest Price: $59.80 USD

0.07 (-0.12%)

Updated Nov 25 7:00pm

Add GMED to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

GMED Stock Summary

  • Price to trailing twelve month operating cash flow for GMED is currently 34.13, higher than 87.7% of US stocks with positive operating cash flow.
  • For GMED, its debt to operating expenses ratio is greater than that reported by just 0.52% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for Globus Medical Inc; that's greater than it is for just 8.96% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Globus Medical Inc, a group of peers worth examining would be ICUI, SSTK, CRTO, ITI, and PLPC.
  • GMED's SEC filings can be seen here. And to visit Globus Medical Inc's official web site, go to www.globusmedical.com.

GMED Stock Price Chart Interactive Chart >

Price chart for GMED

GMED Price/Volume Stats

Current price $59.80 52-week high $60.17
Prev. close $59.87 52-week low $33.41
Day low $59.38 Volume 521,329
Day high $60.00 Avg. volume 886,023
50-day MA $53.57 Dividend yield N/A
200-day MA $50.04 Market Cap 5.90B

Globus Medical, Inc. (GMED) Company Bio


Globus Medical focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company was founded in 2003 and is based in Audubon, Pennsylvania.

GMED Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$59.80$14.88 -74%

Below please find a table outlining a discounted cash flow forecast for GMED, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Globus Medical Inc ranked in the 19th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for GMED, they are:

  • The company's balance sheet shows it gets 100% of its capital from equity, and 0% of its capital from debt. Notably, its equity weight is greater than 95.79% of US equities in the Healthcare sector yielding a positive free cash flow.
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 0.05% of the free cash flow producing stocks we're observing.
  • Globus Medical Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -6.65. This coverage rate is greater than that of merely 10.8% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-75%
1%-75%
2%-74%
3%-74%
4%-74%
5%-74%

Want more companies with a valuation profile/forecast similar to that of Globus Medical Inc? See AZN, CNC, NUVA, CNMD, and LMNX.


GMED Latest News Stream


Event/Time News Detail
Loading, please wait...

GMED Latest Social Stream


Loading social stream, please wait...

View Full GMED Social Stream

Latest GMED News From Around the Web

Below are the latest news stories about Globus Medical Inc that investors may wish to consider to help them evaluate GMED as an investment opportunity.

Global Vertebroplasty and Kyphoplasty Market 2027 In-Depth Analysis Globally by Top Key Players Globus Medical, IZI Medical Products, ZAVATION, RONTIS, G21 S.r.l., SOMATEX Medical Technologies

A new research study from “Data Bridge Market Research” with title Vertebroplasty and Kyphoplasty Insights 2020, Global Analysis and Forecast to 2027 provides an in-depth assessment of the Vertebroplasty and Kyphoplasty including key market trends, upcoming technologies, industry

OpenPR | October 1, 2020

Orthopedic Biomaterials Market to Reach USD 26.28 Billion By 2027 | Evonik Industries AG, Zimmer Biomet, Globus Medical, etc.

The current report on the Orthopedic Biomaterials Market provides a comprehensive assessment of the business vertical and offers a comprehensive overview of the industry along with its key segments. The study includes an accurate estimate of the current industry scenario

OpenPR | September 30, 2020

Stryker Has Looked A Little Mortal Lately, And The Stock Has Suffered

To be clear from the outset, the only thing that’s “wrong” with Stryker (SYK) is that the company’s past performance, and the sell-side’s endless need to find ways to goose price targets ever higher, set a pace that few companies could maintain. Then COVID-19 came along and made life considerably...

Stephen Simpson, CFA on Seeking Alpha | September 1, 2020

NuVasive's Valuation Prices In An Excessively Bearish Outlook

When a med-tech stock, particularly an established one, seems to be undervalued on the basis of both its cash flow and growth, it’s wise to reconsider your assumptions. While NuVasive (NUVA) enjoyed a honeymoon period after Chris Barry was brought on as CEO, the company has been smacked by COVID-19,...

Stephen Simpson, CFA on Seeking Alpha | August 27, 2020

Global Spinal Fusion Market 2015-2030: Key Trends, Regional & Competitive Insights, COVID-19 Impact - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Spinal Fusion (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This market model discusses in detail the impact of COVID-19 on Spinal Fusion market for the year 2020 and beyond. Companies Mentioned Medtronic plc NuVasive Inc. DePuy Synthes Inc. Globus Medical Inc. Stryker Corp. Zimmer Biomet Holdings Inc. Lumbar fusions are the most common spinal fusion procedures

Business Wire | August 12, 2020

Read More 'GMED' Stories Here

GMED Price Returns

1-mo 20.52%
3-mo 5.90%
6-mo 9.42%
1-year 5.97%
3-year 58.66%
5-year 123.22%
YTD 1.56%
2019 36.04%
2018 5.30%
2017 65.66%
2016 -10.82%
2015 17.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9102 seconds.